Emerald Health Therapeutics Promotes Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing
October 11 2018 - 7:00AM
Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF)
(“Emerald”) today announced the promotion of Paul R. Dillman, Jr.
to Executive Vice President of Global Sales and Marketing. Mr.
Dillman previously served as Vice President of Sales and Marketing,
and will now be responsible for leading international marketing,
sales, and customer services for Emerald as the company prepares to
participate in the new legal cannabis landscape.
“Paul has been instrumental in preparing the
Emerald brand for adult-use legalization in Canada,” said Chris
Wagner, Chief Executive Officer of Emerald. “With our branding,
marketing and sales strategy, Emerald is poised to be a premiere
provider of cannabis for medical and adult-use consumers. Paul’s
marketing expertise has been invaluable to our team over the past
few months, and we look forward to positioning Emerald to be a
leader in Canada as well as the global cannabis industry.”
Mr. Dillman has three decades of experience in
global marketing, sales, and general management and prior to
Emerald, held senior leadership positions at The Coca-Cola Company,
AB InBev, Philip Morris, and Kraft Foods. Mr. Dillman earned a
bachelor of science from West Point (United States Military
Academy) and a master of science in systems management from the
University of Southern California.
The Company has granted 50,000 stock options to
Mr. Dillman to purchase up to an aggregate of 50,000 common shares
of the Company at an exercise price of $4.60 per Option Share,
vesting over a period of three years and exercisable for five years
from the date of grant.
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF;
Frankfurt: TBD) is a Licensed Producer under Canada’s Access to
Cannabis for Medical Purposes Regulations and produces and sells
dried cannabis and cannabis oil for medical purposes. Emerald owns
50% of Pure Sunfarms, which is converting a licensed existing 1.1
million square foot greenhouse in Delta, BC, and is in commercial
production. It owns Agro-Biotech, a Québec-based licensed cannabis
grower with a 75,000 square foot indoor facility. Emerald has also
entered into hemp chaff purchase agreements in 2018 and subsequent
years. Emerald’s team is highly experienced in life sciences,
product development, large-scale agri-business, and marketing, and
is focused on developing value-added cannabis-based products with
potential wellness and medical benefits. Emerald is part of the
Emerald Health group, which is broadly focused on developing
pharmaceutical, botanical, and nutraceutical products that may
provide wellness and medical benefits by interacting with the human
body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more
information or contact:Rob Hill, Chief Financial Officer(800) 757
3536 Ext. #5
Ray Lagace, Investor Relations Manager(800) 757
3536 Ext. #5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include legalization of nonmedicinal cannabis; Emerald becoming a
premiere provider of cannabis; and expansion of facilities.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labor;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Sep 2023 to Sep 2024